A bigger problem in kids than most parents realize
Blood clots aren't usually thought of as a children's problem. But they do happen — sometimes after surgery, sometimes after a long illness, and sometimes from cancer treatment or congenital heart conditions.
When they do, the treatment is often the same one used in adults decades ago: blood-thinning shots that have to be given daily, often at the hospital or by a parent at home.
A new review suggests something better may finally be coming for kids.
Blood clots are increasingly recognized in children. Hospital stays, central lines, and certain medical conditions all raise the risk. When a clot forms, it can block blood flow to a leg, lung, or other organ — sometimes with life-threatening consequences.
Treatment usually involves heparin or related medicines, given as injections or IV drips. They work, but they require frequent monitoring and can disrupt a child's daily life. Switching to a pill — if it's safe and effective — would be a major quality-of-life win.
For adults, that switch already happened a decade ago. Direct oral anticoagulants, called DOACs, replaced shots for most patients. Children are only now catching up.
The old way versus the new way
Standard care for childhood clots has long meant heparin shots or IV drips, often followed by warfarin pills with frequent blood tests to keep dosing correct. Both work but require careful monitoring.
DOACs work differently. They block specific clotting proteins more directly, with predictable dosing and no need for constant blood tests. For adults, that has meant fewer hospital visits, more flexible dosing, and a noticeable drop in major bleeding events.
The question this review tackles is whether children get those same benefits — without trading off effectiveness or safety.
How DOACs work in the body
Imagine the clotting system as a chain of dominoes. When the body needs a clot, the dominoes fall in sequence until a clot forms.
Older blood thinners like warfarin knock down many of the dominoes at once, which works but is hard to control. DOACs target one specific domino — usually a protein called factor Xa or thrombin — and stop the chain right at that point.
Because the action is more focused, the dose is more predictable. Daily blood tests aren't needed in most cases. For families and children, that means fewer needles and fewer doctor visits.
The study snapshot
The team searched major medical databases through November 2025 for randomized clinical trials comparing DOACs with standard care in children. Eight trials covering 2,002 pediatric patients met the inclusion criteria. They pooled results on whether clots came back during treatment, whether new clots formed during prevention, and how often patients had bleeding or other serious side effects.
For treatment of existing clots, DOACs cut the rate of recurrence in half compared to standard care. For prevention, DOACs lowered the chance of a new clot by about 37%.
On the safety side, major bleeding was similar between the two groups, with a slight trend favoring DOACs. Serious adverse events and overall mortality were also similar.
Put simply: in this pooled analysis, the newer oral medicines worked better at preventing repeat clots and were no more dangerous than the standard treatments.
This doesn't mean every child with a clot should switch to a DOAC tomorrow.
Where this fits in the bigger picture
Pediatric medicine often runs years behind adult medicine when it comes to adopting new drugs. The reason is simple: trials in children are harder to enroll, take longer, and need careful safety monitoring because growing bodies handle medicines differently.
The fact that DOACs now have eight pediatric clinical trials behind them — covering more than 2,000 children — is a major step. Several of these drugs already have specific pediatric approvals from regulators in the US and Europe.
This review pulls the evidence together at a moment when many children's hospitals are deciding whether to switch their default treatment.
If your child has been diagnosed with a blood clot or is at high risk for one, this study supports asking the medical team whether a pediatric-approved DOAC is an option. Several are now available in age-appropriate forms, including liquids and dispersible tablets for younger children.
The decision still depends on the specific child — their condition, weight, kidney function, other medications, and the type of clot. But the older one-size-fits-all approach of heparin shots is being replaced with more options.
Eight trials with 2,002 patients is solid for pediatrics but small compared to the adult evidence base. The trials covered a mix of conditions and didn't all use the same DOAC, so the pooled estimate hides differences between drugs. Long-term safety in growing children — especially over years of use — is still being studied. And the results may not apply equally to all pediatric subgroups, especially newborns.
Several pediatric trials are still ongoing, including studies in younger infants and in children with specific underlying conditions like congenital heart disease. Real-world registries tracking children on DOACs over many years will fill in the long-term safety picture. As that data grows, oral blood thinners are likely to become the new default for many pediatric clotting conditions.